distinguishing the 2 processes which frequently merged in the same sections. Furthermore, the results eventually obtained were similar in the 2 lesions. The mean ages of the patients are given in Table 1 . The menopausal status or stage of menstrual cycle for each patient was not known.
Mitotic counting in breast cancers
The number of mitoses within 10 high powered fields (hpf, magnification × 400, field diameter 640 µm) was calculated for all the invasive breast cancers. Mitotic figures were recognized according to the criteria described by Baak and Oort (1983) . In addition the mitotic activity index (MAI) was calculated and expressed as the number of mitoses per 1000 cells. These were then correlated with the percentage of cyclin D 1 and Ki67-positive cells within the cancers.
Dual immunofluorescence immunohistochemistry
Dual immunofluorescent immunohistochemistry was performed by combining a primary monoclonal mouse antibody with a primary polyclonal rabbit antibody. The monoclonal antibodies used were ER 1D5 (Dako, Cambridge, UK) and cyclin D 1 (Dako) and the polyclonal antibodies were Ki67 (Novacastra, Newcastle upon Tyne, UK) and ER (Santa Cruz Biotechnology Inc, Santa Cruz, California, USA). In order to verify that both ER antibodies were staining the same cells, dual immunofluorescence was performed with the 2 ER antibodies on normal breast tissue and on invasive carcinomas. 4 micrometer sections were cut onto 2% aminopropyltriethoxysilane (APES)-coated slides and dried overnight at 45˚C. The sections were dewaxed in 2 changes of xylene followed by 2 changes of industrial methylated spirits and then rinsed in deionized water. Pretreatment comprised microwaving for 15 min at full power in 10 mM EDTA (pH 7). A mixture of both primary antibodies (diluted in 5% bovine serum albumin [BSA]/Tris buffered saline [TBS] ) was then applied for 80 min. The dilution used for ER 1D5 was 1/30, for Ki67 1: 100, for cyclin D 1 1:20 and for polyclonal ER 1:30. BSA/TBS was applied to all negative controls. A mixture of both secondary antibodies, diluted in 5% BSA/TBS, was then applied for 30 min. The secondary antibodies used were TRITC-conjugated swine anti-rabbit antibody 1:50 (Dako) and biotinylated sheep anti-mouse antibody 1:100 (Amersham Life Sciences, UK). Next fluorescein-avidin conjugate (Dako) 1:100 (diluted in 5% BSA/TBS) was applied for 30 min. Washes in TBS were performed between each step. Finally the slides were immersed in a solution of 4′, 6-diamidino-2-phenylindole (Sigma, Poole, UK) at a concentration of 250 ng ml -1 in TBS for 10 min. The slides were then coverslipped and mounted using an antifading medium (Vectashield, Vector Laboratories, UK).
Assessment of immunostaining
Quantification of the fluorochrome-labelled cells was performed by either scoring the entire lesion or approximately 1000 cells across several representative fields (chosen using a 4′,6-diamidino-2-phenylindole filter). Each field was examined under a high power lens for the red (TRITC), green (fluorescein) and blue (4′, 6-diamidino-2-phenylindole) fluorochromes using the appropriate filters in succession to assess the presence or absence of double-labelled cells. A triple band filter in which all three fluorochromes could be seen simultaneously was used for confirmation of dual staining. If normal breast tissue was present around the benign or malignant lesions studied then it was also examined.
Data analysis
For all normal and pathological categories the percentage of cells staining for each marker and for both were calculated. Also calculated were the percentage of double-labelled cells that would be expected if the 2 variables were independent. This was calculated by multiplying the percentage of cyclin D 1 and Ki67-positive cells or the percentage of cyclin D 1 and ER-positive cells and then dividing by 100 for each individual lesion. The actual number of dual positive cells and the number expected were then compared using the paired t-test. The observed/expected (O/E) ratio gives an indication of whether, in any of the lesions studied, the 2 markers were positively or negatively associated with each other and the strength of the association. In the former, values of greater than 1 would be expected and in the latter, less than 1. The data were also analysed by using Pearsons Product Moment Correlation Coefficient (PPMCC) and the Mann-Whitney and Kruskal-Wallis tests using SPSS software for Windows NT.
RESULTS

Comparison of monoclonal ER 1D5 and polyclonal ER antibodies
Dual staining for both ER antibodies was performed in 9 cases of normal breast and 5 IDC (3 ER-positive). A perfect positive correlation was achieved in both normal breast and IDC (PMCC r = 1.00, P < 0.0001). Of the 1920 ER-positive cells identified in normal breast using the ER 1D5 antibody, more than 99% of the cells were also positive with the polyclonal ER antibody. The converse was also true.
Cyclin D 1 , ER and Ki67 in normal breast
In normal breast Ki67 positive cells represented approximately 3% of the epithelial cell population whilst only 0.3% of cells contained immunodetectable cyclin D 1 (Table 1) . Approximately 1300 Ki67-positive cells were identified in normal breast, however, none coexpressed cyclin D 1 . The mean percentage of ER-positive cells in normal breast was 20% (samples mainly from women in the perimenopausal age group) and in these specimens approximately half of the cyclin D 1 -positive cells coexpressed ER ( Table 2 ). The cyclin D 1 -positive cells were more likely to express ER than the cyclin D 1 -negative cells (paired t-test for observed vs expected values P = 0.04) and were less likely to coexpress Ki67 (paired t-test for observed vs expected values P < 0.0001). In addition, the percentage of Ki67-positive cells decreased with increasing age (PPMCC, r = -0.427 P < 0.0001) whilst the percentage of cyclin D 1 -positive cells increased with increasing age (PPMCC, r = 0.255 P = 0.02).
Cyclin D 1 , ER and Ki67 in invasive cancer
Invasive breast cancers had a high percentage of Ki67 positive cells (Table 1) , the percentage was significantly higher in ER-negative than ER-positive tumours (Mann-Whitney P = 0.01). Cyclin D 1 -positive cells were found in 70% of ER-positive IDC and in 30% of ER-negative IDC. However, the number of cases that were considered positive for cyclin D 1 depended upon the cut-off point used (Table 3 ). The mean percentage of cyclin D 1 -positive cells was significantly higher than that seen in normal breast tissue for ER-positive (Mann-Whitney P = 0.004) but not for ERnegative (Mann-Whitney, P = 0.9) breast cancers. However, no cells coexpressing cyclin D 1 and Ki67 were seen in ER-negative IDC and only in 2 cases (20%) of ER-positive IDC were cells coexpressing cyclin D 1 and Ki67 identified, although even in these cases the majority of cyclin D 1 cells did not coexpress Ki67. In contrast, there was a strong positive correlation between the percentage of cyclin D 1 -positive and ER-positive cells (PPMCC, r = 0.617, P = 0.0004).
Mitoses and their relationship to Ki67 and cyclin D 1 in invasive cancer
A mean of 2033 (SD 765) cells were counted for each case with a mean MAI of 7.7. The median number of mitoses per 10 hpf was 18. The MAI and the number of mitoses per 10 hpf showed a strong correlation with the percentage of Ki67-positive cells (PPMCC, r = 0.669, P = 0.001 and r = 0.562, P = 0.01, respectively). However, no significant correlation was found between the MAI or the number of mitoses per 10 hpf and the percentage of cells expressing cyclin D 1 (PMCC r = -0.251, P = 0.3 and r = -0.252, P = 0.3, respectively).
Cyclin D 1 and Ki67 within proliferative breast disease
Hyperplasia without atypia HUT had a significantly higher mean percentage of cyclin D 1 -positive cells than normal breast (Mann-Whitney, P = 0.03) and a higher mean percentage of cells coexpressing Ki67 and cyclin D 1 (Mann-Whitney, P < 0.0001) although the mean percentage of Ki67-positive cells was similar (Mann-Whitney P = 0.23, Table 1 ). However, HUT had a lower mean percentage of cyclin D 1 -positive cells than ADH and DCIS LNG (Mann-Whitney, highest P = 0.009). HUT also had a lower mean percentage of Ki67-positive cells than that seen in ADH and all grades of DCIS (Mann-Whitney, highest P = 0.04). Of the 247 cyclin D 1 -positive cells identified in all HUT only 4 cells coexpressed Ki67. Table 3 ).
Other benign breast lesions
The other benign breast lesions associated with an increased risk of 1.5-2.0 of subsequently developing breast cancer e.g. sclerosing adenosis, radial scar, papilloma and fibroadenoma, had a wide range of values for the mean percentage of cyclin D 1 -and Ki67-positive cells (Table 1) . Some of the lesions had values similar to normal breast, others similar to HUT and yet still others with values similar to ADH. However, in all breast lesions studied, cells coexpressing cyclin D 1 and Ki67 were either not present or only present very infrequently (Table 1, Table 3 ). The mean observed /expected value for all lesions, except lactating breast, was below 1 (Figure 1 ). The high observed/expected ratio noted in lactating breast was because only 3 cyclin D 1 -positive cells were identified of which 2 coexpressed Ki67.
DISCUSSION
Cyclin D 1 is known to be important in cell cycle control by regulating progression through the G 1 phase of the cell cycle (Sutherland et al, 1995) . Ki67 is a marker of proliferation and in the present study correlated strongly with the mitotic count and the MAI. Ki67 has also been shown to correlate with radioactive thymidine labelling when used as a cell cycle marker (Clarke et al, 1997) . However, interestingly we did not see any Ki67-positive cells coexpressing cyclin D 1 in normal breast despite looking at over 1300 Ki67-positive cells. In breast cancer cyclin D 1 overexpression by immunohistochemistry is associated with low-grade ER-positive breast cancers that have a low proliferation rate (van Diest et al, 1997) . In our study, in ER-negative breast cancers that contained a high percentage of Ki67-positive cells few or no cyclin D 1 -positive cells were detected. Cyclin D 1 -positive cells that were present did not coexpress Ki67. De Jong et al (1999) used dual staining immunofluorescence for cyclin D 1 and Ki67 on 6 cancers, 3 of which were from the breast. Coexpression of cyclin D 1 and Ki67 was not seen in the breast cancers but 2 squamous cell carcinomas from the head and neck region contained occasional duallabelled cells in the basal layers. Although co-expression of cyclin D 1 and Ki67 is occasionally seen within the in situ proliferations, cyclin D 1 -positive cells generally are less likely to be dividing than the cyclin D 1 -negative cells. Hence in the majority of cases, it would appear that cyclin D 1 expression is not associated with cell cycle progression.
In normal breast we found that cyclin D 1 and ER were positively associated. Furthermore, the percentage of cyclin D 1 -positive cells increased with age, a similar effect was seen for ER in normal breast (Shoker et al, 1999b) . This supports the finding that cyclin D 1 is an ER-regulated gene (Sutherland et al, 1995) , possibly being more likely to be switched on in environments in which low serum oestrogen concentrations prevail allowing cells to differentiate along an ER-positive pathway. Cyclin D 1 -positive cells were also more likely to be present within ER-positive than ER-negative DCIS and invasive cancer. The disparity between the amplification of the cyclin D 1 gene and the overexpression of cyclin D 1 protein in breast cancers (Barnes, 1997) may therefore be due to the dysregulation of ER that occurs in the majority of these lesions (Shoker et al, 1999a (Shoker et al, , 1999b (Shoker et al, , 2000 . The mutual expression of cyclin D 1 and ER could allow the direct stimulation of ER pathways in the absence of oestrogen and may have an important role in the aetiology of ER positive cancers (Zwijsen et al, 1997) .
The overexpression of the cyclin D 1 gene has been associated with high telomerase activity without an increase in tumour cell proliferation (Landberg et al 1997) . In a mammary epithelial cell line, transduction of cyclin D 1 inhibited growth, possibly due to prolongation of the S-phase (Han et al, 1995) . Similarly, expression of ER in previously ER-negative cell lines leads to growth inhibition (Zajchowski et al, 1993) . The prevention of ER or cyclin D 1 -expressing cells to enter division is possibly achieved by the action of cyclin-dependent kinase inhibitors, e.g. p21
Cip1 and p27 Kip1 , which have been described as markers of differentiation in breast epithelia. Cells overexpressing cyclin D 1 also frequently coexpress p21
Cip1 (de Jong et al, 1999) and, in grade I breast cancers, p27
Kip1 expression is correlated with both ER and cyclin D 1 (Leong et al, 2000) . Whilst both ER and cyclin D 1 play an important role in cellular proliferation and in tumorigenesis, their action would seem to favour differentiation and thus lead to an association with less aggressive breast tumours. The expression of cyclin D 1 may therefore be important in both proliferation and differentiation, the pathway followed depending upon other cell cycle regulators that are also present within the cell.
Overexpression of the cyclin D 1 protein is common in breast cancer (Barnes, 1997) . In transgenic mice, when the cyclin D 1 gene is linked to the mouse mammary tumour virus promoter, the mice develop precancerous hyperplasias and only after long latent periods do they develop carcinomas (Wang et al, 1994) . Thus a number of studies have looked at precancerous breast lesions to see whether this represents an early change in the progression to neoplasia. One of the first studies looked at cyclin D 1 mRNA expression using in situ hybridization. It found overexpression in 18% of benign breast lesions and ADH and in 76% of LNG DCIS, 87% HNG DCIS and 83% IDC and suggested that cyclin D 1 may be useful in separating benign and premalignant breast lesions from any form of breast carcinoma (Weinstat-Saslow et al, 1995) . Gillett et al (1998) looked at protein overexpression by immunohistochemistry and found that it was present in 64% of cases of DCIS and in only 14% of cases of ADH although a further 7 of 9 cases did show weak staining. A number of other studies have found a graded increase in cyclin D 1 overexpression from normal to HUT to ADH to DCIS and finally to invasive cancer with significant differences not always being seen between the lesions (Alle et al, 1998; Mommers et al, 1998; Zhu et al, 1998) . Our own findings agree with these latter studies. The mean percentage of cyclin D 1 -positive cells is higher within the in situ proliferations than in normal breast. ADH had values higher than those seen for HUT but similar to those seen in ER-positive DCIS. The percentage of cyclin D 1 -positive cells in these lesions thus seems to correlate with the percentage of ER-positive cells also found in these lesions (Shoker et al, 1999a (Shoker et al, , 1999b (Shoker et al, , 2000 . However, the other low-risk breast lesions contain a variable percentage of cyclin D 1 -positive cells, some lesions have similar values to HUT whilst other have higher values that approach the atypical proliferations. The usefulness of cyclin D 1 in separating benign from malignant lesions is therefore not clear cut. 
